Brugada Syndrome 7 (BrS7): A Comprehensive Disease Characterization Report

Disease: Brugada syndrome 7 · Gene: SCN3B (Navβ3) · OMIM: #613120 · Category: Genetic (cardiac channelopathy) Evidence status: SCN3B has "limited" gene–disease validity for Brugada syndrome (SCN5A is the sole "definitive" gene)

Autonomous literature-based investigation. Evidence types are flagged as [human clinical], [in vitro], [model organism], [computational], or [database]. Where primary data specific to the SCN3B/BrS7 subtype are lacking, general Brugada-syndrome (BrS) evidence is used and labeled as such.

Summary

Brugada syndrome 7 (BrS7; OMIM #613120) is a rare, autosomal-dominant cardiac sodium channelopathy attributed to loss-of-function variants in SCN3B, the gene encoding the auxiliary β3 subunit (Navβ3) of the cardiac voltage-gated sodium channel. Mutant β3 fails to properly chaperone and modulate the pore-forming Nav1.5 (SCN5A) α-subunit, reducing its cell-surface expression and cardiac sodium current (I_Na) [in vitro, 23257389]. The reduced inward sodium current unmasks transient-outward-current (I_to)-mediated repolarization heterogeneity in the right ventricular outflow tract (RVOT), which generates the diagnostic type-1 (coved) Brugada ECG pattern and creates a phase-2-reentry substrate for polymorphic ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD) [in vitro, 24657694].

Clinically, BrS7 is indistinguishable from other Brugada subtypes. It presents predominantly in adult males (~95% male, mean age ~51 years), is unmasked or triggered by fever, sodium-channel-blocking drugs, enhanced vagal tone, and electrolyte imbalance, and is managed with implantable cardioverter-defibrillators (ICDs), quinidine, isoproterenol/adrenaline for electrical storms, epicardial RVOT substrate ablation, and trigger avoidance. There is no gene-specific therapy for the SCN3B subtype.

A critical caveat governs the entire entity: evidence-based gene-curation (ClinGen-style reappraisal by Hosseini et al., 2018) classified SCN3B as having only "limited" clinical validity for Brugada syndrome, with SCN5A being the only gene reaching "definitive" evidence [PMID 29959160]. Contemporary expert consensus reinforces that SCN5A "remains the sole gene with definitive disease association" and that BrS displays complex, oligogenic/polygenic inheritance [PMID 41738055]. BrS7 is therefore best regarded as a rare, disputed monogenic subtype nested within a broader genetic architecture. This report is compiled from aggregated disease-level resources (OMIM, HGNC, UniProt) and primary literature (human clinical cohorts, in-vitro electrophysiology, and a Scn3b-knockout mouse), not individual EHR data.

Key Findings

Finding 1 — BrS7 is caused by loss-of-function SCN3B variants that reduce cardiac sodium current via impaired Nav1.5 trafficking

BrS7 (OMIM #613120) is caused by heterozygous mutations in SCN3B, encoding the auxiliary β3 subunit (Navβ3) of the cardiac sodium channel. In the seminal functional study of the Japanese SCN3B-V110I variant, transfected cells showed decreased Nav1.5 cell-surface expression and significantly reduced sodium current — a clear loss-of-function effect. As the authors reported, "The SCN3B mutation impaired the cytoplasmic trafficking of Nav1.5, the cell surface expression of which was decreased in transfected cells," and "Whole-cell patch clamp recordings of the transfected cells revealed that the sodium currents were significantly reduced by the SCN3B mutation" [in vitro, 23257389]. A newly characterized in-frame deletion (p.T138del, 2025) confirms ongoing identification of BrS-associated SCN3B variants; the paper "identify and characterise a novel SCN3B variant encoding the regulatory β3-subunit of the cardiac voltage-gated sodium channel" [human/in vitro, 39761910]. This establishes the core molecular lesion: reduced I_Na from a defective auxiliary subunit.

Finding 2 — SCN3B is a rare cause of SCN5A-negative Brugada syndrome (~1.7% in a Japanese cohort)

Among 181 unrelated SCN5A-negative BrS patients (178 Japanese, 3 Korean), the SCN3B Val110Ile variant was found in only 3 of 178 (1.7%) Japanese patients and was absent from 480 Japanese controls: "A mutation, Val110Ile, was identified in 3 of 178 (1.7%) Japanese patients, but was not found in 480 Japanese controls" [human, 23257389]. Set against the broader diagnostic landscape — "A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis" [human clinical, 38426305] — SCN3B accounts for a small fraction of the minor BrS genes.

Finding 3 — The Scn3b-knockout mouse recapitulates conduction slowing and atrial arrhythmia susceptibility

Scn3b(−/−) mice showed slower heart rates, longer P-wave durations, and prolonged PR intervals versus wild-type, plus abnormal atrial electrophysiology and inducible atrial tachycardia/fibrillation on burst pacing. As reported, "Lead I electrocardiograms from Scn3b(-/-) mice showed slower heart rates, longer P wave durations and prolonged PR intervals than WT hearts," and "Atrial burst pacing protocols induced atrial tachycardia and fibrillation in all Scn3b(-/-) but hardly any WT hearts" [model organism, 19796257]. Because Scn1b and Scn5a mRNA were unchanged, the phenotype is attributable specifically to β3 loss.

Finding 4 — The BrS arrhythmia substrate arises from RVOT epicardial repolarization heterogeneity and concealed phase-2 reentry

In coronary-perfused canine RV wedge preparations pharmacologically mimicking the BrS genotype (I_to-agonist NS5806 + Ca-channel blocker verapamil), "Fractionated electrical activity was observed in RV epicardium, but not in endocardium, as a consequence of heterogeneities in the appearance of the second upstroke of the epicardial action potential, and discrete high-frequency spikes developed as a result of concealed phase 2 re-entry" [in vitro, 24657694]. Contemporary consensus reframes BrS as a microstructural–electrical continuum: "BrS, once viewed as a purely electrical disorder, is now recognized along a microstructural-electrical continuum, with sodium-channel dysfunction and subtle epicardial fibrosis of the right ventricular outflow tract as key contributors" [human clinical, 41738055].

Finding 5 — Fever, sodium-channel-blocking drugs, vagal tone, and electrolyte imbalance unmask the type-1 pattern and trigger arrhythmias

Fever is a well-established trigger that unmasks the coved type-1 ECG and precipitates VF, including as a first manifestation across ages. Reviews list precipitating factors succinctly: "Brugada syndrome could be precipitated by various factors, such as fever, electrolyte imbalances, and drugs" [human clinical, 42411811], and "Fever is a well-known trigger for malignant ventricular arrhythmias in predisposed patients" [human clinical, 42200267]. This is the paradigmatic gene–environment interaction of the disease.

Finding 6 — Management centers on ICD and quinidine, with epicardial RVOT substrate ablation as an emerging therapy

"For decades, treatment centered on implantable cardioverter-defibrillators and quinidine, both limited by availability, tolerance, and device complications. More recently, epicardial substrate ablation has emerged as a transformative therapy" [human clinical, 41738055]. Quinidine efficacy is quantified in an Israeli survey with "inducible ventricular fibrillation (VF) in 10, which was prevented by quinidine in 9/10 patients" [human clinical, 29761670]. There is no gene-specific therapy for SCN3B-related BrS7.

Finding 7 — BrS is strongly male-predominant with mid-adult presentation; SCN5A is the only definitively validated gene

Large Japanese prospective registries report cohorts of ~95% men with mean age ~51 years: "We analyzed 510 patients with BrS (mean age 51 ± 14 years; 95% men)" [human clinical, 41819241]. Expert consensus states "SCN5A remains the sole gene with definitive disease association, while polygenic susceptibility materially modulates risk, underscoring complex inheritance" [human clinical, 41738055] — implying minor genes including SCN3B have limited monogenic validity.

Finding 8 — SCN3B has only LIMITED clinical validity as a Brugada syndrome gene

In the evidence-based reappraisal of BrS genes (ClinGen-style semiquantitative scoring, three independent curation teams + clinical domain expert panel), "Of 21 genes curated for clinical validity, biocurators classified only 1 gene (SCN5A) as definitive evidence, whereas all other genes were classified as limited evidence" [computational/curation, 29959160]. SCN3B (the basis of the BrS7/#613120 designation) falls among the limited-evidence genes.

Finding 9 — SCN3B loss-of-function variants also cause early-onset lone atrial fibrillation (an allelic phenotype)

Olesen et al. sequenced SCN3B in 192 unrelated lone AF patients and found three non-synonymous mutations (R6K, L10P, M161T), absent from 432 control alleles, all affecting conserved residues: "The three mutations in SCN3B were investigated electrophysiologically and all led to loss of function in the sodium current, supporting the hypothesis that decreased sodium current enhances AF suscepti[bility]" [in vitro/human, 21051419]. Separately, GATA4-regulated 5′UTR/promoter SCN3B variants were linked to lone AF via a gain-of-function increase in expression [in vitro, 36362949], illustrating context-dependent directionality.

Finding 10 — Diagnosis rests on the type-1 ECG (spontaneous or drug-provoked) and the Shanghai score

Diagnosis requires a coved-type (type-1) ST-elevation ECG in leads V1–V2, spontaneous or unmasked by sodium-channel-blocker provocation (ajmaline/flecainide). A large drug-provocation study "involved 698 patients with drug-induced type 1 BrS, confirmed via pharmacologic challenge (flecainide or ajmaline), from 21 centers in Italy and Switzerland" [human clinical, 40996547]. In that cohort, "SCN5A pathogenic variants were a significant predictor of primary endpoint in the possible BrS group (OR: 12.5)" — showing SCN5A, not minor genes like SCN3B, drives prognostic weight.

Finding 11 — SCN3B encodes Navβ3, a single-pass glycoprotein with an extracellular Ig domain that chaperones and modulates Nav1.5

SCN3B (HGNC:10592; gene OMIM 608214; 11q24.1; UniProt Q9NY72) encodes an auxiliary single-transmembrane protein with an extracellular immunoglobulin (Ig)-like fold and short intracellular tail. It associates non-covalently with Nav1.5, modulating gating and promoting surface trafficking. Reports confirm "the VGSC β3 subunit (the product of SCN3B gene)... its extracellular immunoglobulin domain (β3 Ig)" [in vitro, 40245999] and that "a mutation in SCN3B for a small subunit of sodium channel, Navβ3, has been recently reported" [in vitro, 23257389].

Section-by-Section Characterization

1. Disease Information

BrS7 is a genetic subtype of Brugada syndrome — a primary inherited arrhythmia syndrome characterized by ST-segment elevation in the right precordial ECG leads (V1–V2) and increased SCD risk in a structurally near-normal heart.

Synonyms: Brugada syndrome type 7; BRGDA7; SCN3B-related Brugada syndrome. Historical/allelic clinical descriptors: sudden unexplained nocturnal death syndrome (SUNDS), "Lai Tai," "Bangungut" [human clinical, 24529773]. Data provenance: aggregated disease-level resources plus individual case reports and small functional studies (subtype-specific evidence is sparse).

2. Etiology

Primary cause (genetic): heterozygous variants in SCN3B (Navβ3) [PMID 23257389; 39761910]. Genetic risk factors: V110I (recurrent in Japan), L10P, T138del, A195T (VUS); polygenic background near SCN5A-SCN10A and HEY2 modulates risk [PMID 41738055; 41458990]. Environmental triggers (unmask rather than cause): fever (most important), sodium-channel-blocking drugs, propofol/local anaesthetics, enhanced vagal tone, electrolyte abnormalities, alcohol, cocaine, and male sex [PMID 42411811; 42200267; 41819241]. Protective factors: no validated protective allele; trigger avoidance (aggressive fever control, avoiding contraindicated drugs) is the principal modifiable protection; female sex/older age associate with lower event rates [PMID 40130219]. Gene–environment interaction: the temperature-sensitive mutant channel loses further function during fever, deepening the epicardial repolarization gradient [PMID 42200267].

3. Phenotypes

Onset: predominantly adult (3rd–5th decade); pediatric and elderly first presentations occur. Severity/progression: highly variable and episodic; most carriers asymptomatic; risk lifelong. QoL impact: anxiety about SCD, activity/occupational restrictions, ICD-related psychological burden and inappropriate shocks (ICD complications ~20% in a pediatric cohort) [PMID 31748893]. No disease-specific QoL instrument; generic EQ-5D/SF-36 apply.

4. Genetic / Molecular Information

Causal gene: SCN3B (Navβ3). Reported variants (germline, heterozygous):

ACMG classification: most variants VUS/limited-evidence given disputed gene validity [PMID 29959160]. Allele frequency: rare/absent in controls (check gnomAD per variant). Functional consequence: predominantly loss of function; regulatory gain-of-function branch for AF [PMID 36362949]. Modifier genes: SCN5A genotype + polygenic background [PMID 41738055]. Epigenetics: GATA4 transcriptionally regulates SCN3B [PMID 36362949]; no disease-specific methylation signature or characteristic chromosomal abnormality.

5. Environmental Information

Sodium-channel-blocking drugs, anaesthetics (propofol, bupivacaine), cocaine, and certain tyrosine-kinase inhibitors can unmask the pattern (a Brugada phenocopy was reported with avapritinib during febrile illness) [PMID 42165456; 42411811]. Large meals, alcohol, and dehydration/electrolyte shifts provoke events. Infectious agents: none causative; febrile infections (any cause, e.g., influenza) are a major arrhythmic trigger by unmasking the type-1 pattern [PMID 42647943].

6. Mechanism / Pathophysiology

Ordered causal chain (mutation → clinical manifestation):

1. A heterozygous SCN3B (Navβ3) variant alters the auxiliary β3 subunit [DEMONSTRATED in vitro, 23257389]. →
2. Mutant β3 fails to chaperone/modulate Nav1.5, leading to reduced Nav1.5 surface expression [DEMONSTRATED, 23257389; 39761910]. →
3. This results in reduced peak cardiac sodium current (I_Na) — a loss-of-function channelopathy [DEMONSTRATED by patch clamp, 23257389]. →
4. Reduced I_Na allows the I_to-mediated phase-1 notch to dominate the epicardial action potential, most prominently in RVOT epicardium (highest I_to), leading to loss of the AP dome at some sites [INFERRED from wedge models, 24657694]. →
5. Heterogeneous dome loss creates transmural/epicardial dispersion of repolarization, producing the coved type-1 ST elevation and concealed phase-2 reentry [PMID 24657694]. →
6. Phase-2 reentry triggers closely coupled premature beats initiating polymorphic VT/VF [PMID 24657694]. →
7. VF results in syncope, aborted arrest, or SCD [PMID 41738055].
8. Modulating branch: fever / Na-blockers further reduce I_Na at step 3 [PMID 42200267].
9. Structural branch: subtle RVOT epicardial fibrosis contributes (microstructural–electrical continuum) [PMID 41738055].
10. Atrial branch: the same reduced-I_Na lesion promotes AF and conduction slowing [PMID 21051419; 19796257].

Supporting detail. Molecular pathway/biochemical defect: cardiac Nav (Nav1.5 + β subunits) dysfunction — an ion-channel defect, not metabolic/enzymatic. Suggested GO: GO:0005248 (voltage-gated sodium channel activity), GO:0086010 (membrane depolarization during action potential), GO:0001518 (voltage-gated sodium channel complex), GO:0086067 (bundle of His cell–Purkinje conduction), GO:0086091 (regulation of heart rate by cardiac conduction). Protein dysfunction: loss-of-function via impaired trafficking and altered gating; β3 uses its extracellular Ig domain for α-subunit interaction [PMID 40245999]. Cell types (CL): ventricular cardiomyocyte (CL:0002131), RVOT epicardial myocytes, Purkinje/conduction cells (CL:0000731/CL:0002068), SA-node cells (CL:1000488). Immune/metabolic: not primary. Omics: no established disease-specific transcriptomic/proteomic/metabolomic signature for BrS7.

7. Anatomical Structures Affected

• Organ: heart (UBERON:0000948); system: cardiovascular (UBERON:0004535).
• Primary site: RVOT / RV epicardium (UBERON:0004125; UBERON:0002082) — locus of the arrhythmic substrate [PMID 24657694]. Secondary: atria (UBERON:0002081) and conduction system (UBERON:0004146) — AF and conduction slowing.
• Secondary organ: brain (hypoxic-ischaemic injury from arrest) — a complication.
• Tissue/cell: cardiac muscle tissue (working ventricular/atrial + conduction myocytes); limited epicardial fibrosis (connective).
• Subcellular (GO CC): plasma membrane/sarcolemma, intercalated disc (GO:0014704), voltage-gated sodium channel complex (GO:0001518), endoplasmic reticulum (trafficking, GO:0005783).
• Lateralization: predominantly right-sided (RVOT); biventricular substrate can occur [PMID 42359113].

8. Temporal Development

Congenital genetic defect but clinically adult-onset (mean event age ~40 yr; late presentation to the 8th decade under febrile stress) [PMID 42200267]. Arrhythmia onset is acute/episodic (often at rest/sleep). The ECG substrate is chronic/lifelong; arrhythmic risk is episodic, not progressive; no defined "stages." Event incidence ~1.5%/yr (non-elderly) vs ~0.7%/yr (elderly) [PMID 40130219]. Critical vulnerable windows: febrile illness and administration of contraindicated drugs.

9. Inheritance and Population

Epidemiology (BrS overall): prevalence ~1 in 2,000–5,000, higher in Southeast/East Asia; BrS7/SCN3B is very rare (isolated families/probands). Inheritance: autosomal dominant with incomplete, age-dependent penetrance and variable expressivity [PMID 41458990]. Founder effects/consanguinity: none established; V110I recurs in Japan without a defined founder haplotype. Carrier frequency: not defined; individual variants rare in gnomAD. Demographics: strong male predominance (~8–9:1; ~95% men), attributed to testosterone-dependent I_to; mean age ~51 yr [PMID 41819241; 40130219]; geographic skew toward Asian populations.

10. Diagnostics

Cornerstone: spontaneous or drug-provoked type-1 coved ST-elevation ≥2 mm in ≥1 right precordial lead (V1–V2), including high lead placement [PMID 41738055]. Provocation with ajmaline/flecainide unmasks concealed cases (ajmaline positive in 76% of a suspected pediatric cohort) [PMID 42669184; 40996547]. Shanghai Score System integrates ECG, symptoms, family history, and genetics (≥3.5 = probable/definite) [PMID 40996547]; multiparametric models (Sieira, Brugada-Risk, PAT) [PMID 40314213]. Genetic testing: multigene NGS panel/WES including SCN5A, SCN1B–4B (incl. SCN3B), etc.; SCN5A highest-yield/most actionable, SCN3B findings usually VUS; overall P/LP yield ~20–25% [PMID 38426305]; cascade familial testing recommended [PMID 26230511]. Imaging: echo/CMR to exclude structural disease (ARVC, scar) [PMID 42359113]. Biomarkers/omics: none established. Differential diagnosis: Brugada phenocopies (fever, hyperkalaemia, ischemia, drugs), ARVC, early repolarization syndrome, RVOT-VT, athlete's ECG, atypical RBBB [PMID 42359113; 25548613]. Screening: no newborn/population screening; cascade ECG + genetic screening of first-degree relatives.

11. Outcome / Prognosis

Principal risk is SCD from VF; annual major-arrhythmic-event rate ~1.5%/yr (non-elderly) vs ~0.7%/yr (elderly), ~11% over long follow-up [PMID 40130219; 41819241]. Higher-risk factors: prior aborted arrest/VF, arrhythmic syncope, spontaneous (vs drug-induced) type-1 ECG, notched P wave/atrial conduction delay, SCN5A pathogenic variant; asymptomatic patients are lower-risk [PMID 41819241; 40996547]. SCN3B genotype is not an established independent prognostic marker. Morbidity: VF-related anoxic injury, ICD complications (inappropriate shocks, lead failure ~20% pediatric), electrical storms, AF [PMID 31748893]. Life expectancy: near-normal if high-risk individuals are protected (ICD) and triggers avoided; chronic/lifelong without cure.

12. Treatment

Genotype-agnostic; no SCN3B-specific therapy.

Evidence: quinidine prevented inducible VF in 9/10 [PMID 29761670]; epicardial ablation is transformative for high-risk/recurrent patients [PMID 41738055; 40088219]; isoproterenol/adrenaline rescue for electrical storms [PMID 40800556]. No approved gene/cell/RNA therapy; gene therapy/precision ablation are aspirational goals [PMID 40505939]. Personalized medicine is by risk score/phenotype, not SCN3B genotype.

13. Prevention

Primary: trigger avoidance (fever→antipyretics, avoid BrS-contraindicated drugs, moderate alcohol) [PMID 42411811]; no relevant immunization. Secondary: cascade ECG + genetic screening of first-degree relatives; risk stratification (Shanghai/Sieira) to select ICD candidates [PMID 40996547; 40314213]. Tertiary: ICD, quinidine, epicardial ablation [PMID 40088219]. Genetic counseling: AD 50% transmission risk; preimplantation genetic testing available for inherited cardiac disease, though limited-validity genes like SCN3B complicate variant-based PGT [PMID 38516780]. Public health: region-dependent pre-participation ECG screening and sports-eligibility guidance [PMID 40116545].

14. Other Species / Natural Disease

SCN3B orthologs: mouse Scn3b (NCBI Gene 235281; MGI), rat Scn3b (RGD), and orthologs in most vertebrates; β3's I_Na-modulatory function is evolutionarily conserved [PMID 19796257]. No naturally occurring SCN3B "Brugada" disease is catalogued in OMIA for companion animals/livestock; inherited ventricular arrhythmia/SCD syndromes exist in dogs (e.g., German Shepherd inherited ventricular arrhythmia) but are not SCN3B-defined. The reduced-I_Na → conduction/arrhythmia mechanism is conserved and validated in mouse. Zoonotic/transmission concepts are not applicable (non-infectious genetic disease).

15. Model Organisms

Mouse — Scn3b-knockout [PMID 19796257]: constitutive KO showing slower heart rate, longer P-wave, prolonged PR interval, abnormal sinoatrial/atrial electrophysiology, prolonged sinus-node recovery, and inducible atrial tachycardia/fibrillation (in essentially all KO vs almost no WT); Scn1b/Scn5a mRNA unchanged, isolating the β3 effect. Limitations: emphasizes atrial/conduction phenotypes; the human ventricular RVOT phase-2-reentry VF and spontaneous type-1 ECG are not straightforwardly reproduced (species differences in I_to distribution). Applications: SA-node function, atrial conduction, AF susceptibility.

In-vitro/cellular: heterologous expression (HEK-293/CHO) co-expressing Nav1.5 + mutant β3 for patch-clamp I_Na and trafficking/biotinylation assays [PMID 23257389; 39761910]; β-subunit-eliminated human haploid (BeHAPe) cells to study subunit regulation [PMID 37544648]. Patient-derived iPSC-cardiomyocytes are used broadly for BrS but no SCN3B-specific iPSC model was identified. Resources: MGI (Scn3b), IMPC, RGD.

Mechanistic Model / Interpretation

 SCN3B loss-of-function variant (V110I / L10P / T138del)
                 │  alters Navβ3 auxiliary subunit
                 ▼
 Impaired β3 chaperone/modulatory function          [DEMONSTRATED in HEK293]
                 ▼
 ↓ Nav1.5 (SCN5A) trafficking → ↓ cell-surface channels   [DEMONSTRATED]
                 ▼
 ↓ Peak cardiac sodium current (I_Na)  ◄── fever / Na-blocker drugs / vagal tone (TRIGGERS)
                 │  [INFERRED for RVOT ventricle from canine wedge models]
                 ▼
 I_to dominance in RV epicardium → loss of AP dome (accentuated notch)
                 │
                 ├──► Transmural + epicardial repolarization heterogeneity
                 │            └► Type-1 coved ST elevation (V1–V2)  ── DIAGNOSIS
                 │
                 └──► Concealed PHASE-2 REENTRY (extrasystoles)
                                   │
                                   ▼
                    Polymorphic VT / VF  ──►  Syncope / SCD
                                   ▲
       (+ subtle epicardial RVOT fibrosis: microstructural–electrical continuum)

 Atrial branch: same ↓I_Na lesion → conduction slowing + inducible AF  [KO mouse; human AF variants]

Upstream vs downstream: the mutation and I_Na reduction are upstream; the I_to/repolarization imbalance, phase-2 reentry, and VF are downstream. Fever and drugs amplify anywhere along the I_Na axis. The unifying principle is a reduced-inward-current → repolarization-gradient → reentry cascade localized to the RVOT epicardium — the same final common pathway as SCN5A-related BrS, which is why BrS7 is clinically indistinguishable.

Evidence Base

Supported vs Refuted Hypotheses

Supported: - SCN3B loss-of-function reduces I_Na via impaired Nav1.5 trafficking → BrS ECG [PMID 23257389]. - The BrS substrate is RVOT epicardial repolarization heterogeneity with phase-2 reentry [PMID 24657694]. - Scn3b loss causes conduction slowing/atrial arrhythmia in vivo [PMID 19796257]. - SCN3B is also an allelic cause/susceptibility gene for atrial fibrillation [PMID 21051419].

Refuted / down-weighted: - The premise that SCN3B is a robustly validated monogenic BrS gene is not supported; evidence-based curation rates it "limited," with SCN5A the only definitive gene [PMID 29959160; 41738055].

Limitations and Knowledge Gaps

1. Disputed gene validity — SCN3B has only "limited" clinical validity; the BrS7 designation rests on few families/variants, and some historical assignments may be reclassified.
2. Sparse subtype-specific data — penetrance, prevalence, sex ratio, and prognosis are extrapolated from general BrS cohorts; no large SCN3B-specific natural-history study exists.
3. Model–human gap — the Scn3b-KO mouse reproduces atrial/conduction phenotypes but not the human RVOT ventricular VF substrate; canine wedge models are pharmacological, not SCN3B-genotype-specific.
4. Mechanistic gaps — the T138del variant showed normal surface expression, implying additional (gating/microdomain) mechanisms beyond trafficking [PMID 39761910].
5. No genotype-specific therapy or biomarker — management is generic BrS care; risk models carry high bias.
6. Directionality complexity — SCN3B shows loss-of-function (BrS, AF) and gain-of-function (promoter, AF) in different contexts, complicating variant interpretation.

Proposed Follow-up Experiments / Actions

1. Patient-derived iPSC-cardiomyocytes carrying SCN3B variants (± isogenic correction) with I_Na/I_to phenotyping and optical mapping in engineered RVOT-like tissue — to test the human ventricular substrate directly.
2. Formal ClinGen re-curation of SCN3B incorporating post-2018 variants (e.g., T138del), segregation, and functional data to update gene-validity classification.
3. Population-scale variant assessment in gnomAD/TOPMed to establish allele frequencies and refine ACMG classification of reported BrS7 variants.
4. Genotype-stratified cohort analysis pooling SCN3B carriers across international BrS registries to estimate penetrance, event rates, and therapy response versus SCN5A and gene-negative patients.
5. Structural biology of the β3 Ig domain–Nav1.5 interface (cryo-EM / AlphaFold-Multimer) to map how V110I/T138del disrupt trafficking and gating.
6. Systematic drug-safety curation of I_Na-blocking agents and emerging triggers (e.g., tyrosine-kinase inhibitors) for carrier avoidance lists.

Report compiled from ~61 PubMed records. Key PMIDs: 23257389, 39761910, 19796257, 24657694, 41738055, 29959160, 21051419, 40996547, 40088219, 29761670, 42411811, 42200267, 41819241, 40130219, 38426305, 40245999, 36362949. Evidence source legend: human clinical (cohorts, case reports, consensus), in-vitro electrophysiology (HEK293 heterologous expression, canine wedge), model organism (Scn3b-KO mouse), computational/curation (ClinGen gene validity).